US Aid Cuts Devastate Zambia H.I.V. Fight

Zambia faces a dire H.I.V./AIDS crisis as U.S. funding, essential for decades, is threatened by a contentious new health aid agreement. The Trump administration's proposed deal links continued support to expanded U.S. access to Zambia's mineral resources, with a critical April 30 deadline for acceptance. Failure to sign could mean the complete cessation of U.S. aid, jeopardizing a program that once raised life expectancy from 37 to 67.

The article details the devastating impact of reduced U.S. support, which has led to the dismantling of critical prevention services. Index testing, a program that identified 70 percent of new infections, has been halted. Testing for pregnant women and newborns has been reduced, and widespread community testing has been curtailed. These cuts mean many new infections will go undetected until individuals are gravely ill, potentially infecting others.

Health officials express grave concern over rising infection rates and the loss of interventions that protected vulnerable populations. The situation echoes the devastating period three decades ago when the H.I.V. pandemic overwhelmed Zambia's health system. While the Zambian government is attempting to take over program management, it remains ill-prepared for the financial and logistical responsibilities, particularly regarding medication procurement and supply chains.

The potential loss of U.S. support, even bridge funding, leaves Zambia in a precarious position. The country relies heavily on this aid for antiretroviral drugs, laboratory chemicals, and H.I.V. tests. Without a new agreement, Zambia would be forced to independently manage these critical elements, a task for which it is woefully unprepared, potentially leading to widespread death.